GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2012

IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument

  • IntelligentMDx received a CE Mark for its qualitative Group B Streptococcus (GBS) in vitro diagnostic, IMDx GBS, for use on the Abbott m2000™ system. The assay is used to screen for Group B Streptococcus infection in at-risk pregnant women and women in labor.

    The real-time PCR test can be carried out on either direct swabs or enriched culture broth samples, and generates results for up to 48 patient samples simultaneously in five hours. IntelligentMDx says the assay demonstrates 95.5% sensitivity and 98.3% specificity when carried out on swabs, and 100% sensitivity and specificity when used with enriched culture broth samples.

    IMDx GBS for Abbott m2000 is the third CE-marked test developed under the two firms’ multiyear agreement to develop tests for the Abbott platform. Real-time PCR assays for detecting vancomycin-resistant enterococci, and toxigenic C. difficile, have previously received CE Mark approval. Under terms of the firms’ IVD agreement, IMDx is responsible for designing, developing, obtaining regulatory clearance, and manufacturing assays for the m2000 instrument.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?